MERIENNE, Camille; ROUSSET, Marine; DUCINT, D.; CASTAING, N.; TITIER, Karine; MOLIMARD, Mathieu; BOUCHET, Stephane

doi:10.1016/j.jpba.2017.11.060

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

MERIENNE, Camille
Bordeaux population health [BPH]

ROUSSET, Marine
Bordeaux population health [BPH]

DUCINT, D.

Langue

Article de revue

Ce document a été publié dans

Journal of Pharmaceutical and Biomedical Analysis. 2018-02-20, vol. 150, p. 112-120

Résumé en anglais

Several studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKI) can improve their benefit in cancer. An analytical tool has been developed in order to quantify 17 tyrosine kinase inhibitors and 2 metabolites in human plasma (afatinib, axitinib, bosutinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, ponatinib, regorafenib, regorafenib M2, regorafenib M5, ruxolitinib, sorafenib, sunitinib, vandetanib). Drugs were arranged in four groups, according to their plasma concentration range: 0.1-200ng/ml, 1-200ng/ml, 4-800ng/ml and 25-5000ng/ml. Solid phase extraction was used and separation was performed with HPLC using a gradient system on a solid core particle C18 column (5x2.1mm, 1.6mum). Ions were detected with a triple quadrupole mass spectrometry system. This assay allows rapid determination of 19 TKI in less than 5min per run. This high throughput routine method will be useful to adjust doses of oral anticancer drugs in order to improve treatments efficacy.< Réduire

Mots clés en anglais

PharmacoEpi-Drugs

Métadonnées

Partager cette publication !

Licence d’utilisation du document

High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche